Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left" colspan="2"> </td><td class="align_center">Undecided</td><td class="align_center">ET</td><td class="align_center">ET + CT</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left" rowspan="2">Low RS</td><td class="align_center">Pregenomic plan</td><td class="align_center">6</td><td class="align_center">3</td><td class="align_center">12</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">17</td><td class="align_center">4</td></tr><tr><td class="align_left" rowspan="2">Intermediate RS</td><td class="align_center">Pregenomic plan</td><td class="align_center">7</td><td class="align_center">3</td><td class="align_center">16</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">7</td><td class="align_center">19</td></tr><tr><td class="align_left" rowspan="2">High RS</td><td class="align_center">Pregenomic plan</td><td class="align_center">1</td><td class="align_center">0</td><td class="align_center">2</td></tr><tr><td class="align_center">Postgenomic plan</td><td class="align_center">0</td><td class="align_center">0</td><td class="align_center">3</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Therapeutic plans pregenomics and postgenomics testing according to Oncotype DX Recurrence Scores for 50 patients.</div>

Journal of Oncology

tab3

Table 3

Table 3: Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients 